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Abstract
The ongoing bioethical debate on pharmacological cognitive enhancement (PCE) in healthy
individuals is often legitimated by the assumption that PCE will widely spread and become
desirable for the general public in the near future. This assumption was questioned as PCE
is not equally save and effective in everyone. Additionally, it was supposed that the willing-
ness to use PCE is strongly personality-dependent likely preventing a broad PCE epidemic.
Thus, we investigated whether the cognitive performance and personality of healthy individ-
uals with regular nonmedical methylphenidate (MPH) use for PCE differ from stimulant-
naïve controls. Twenty-five healthy individuals using MPH for PCE were compared with 39
age-, sex-, and education-matched healthy controls regarding cognitive performance and
personality assessed by a comprehensive neuropsychological test battery including social
cognition, prosocial behavior, decision-making, impulsivity, and personality questionnaires.
Substance use was assessed through self-report in an interview and quantitative hair and
urine analyses. Recently abstinent PCE users showed no cognitive impairment but superior
strategic thinking and decision-making. Furthermore, PCE users displayed higher levels of
trait impulsivity, novelty seeking, and Machiavellianism combined with lower levels of social
reward dependence and cognitive empathy. Finally, PCE users reported a smaller social
network and exhibited less prosocial behavior in social interaction tasks. In conclusion, the
assumption that PCE use will soon become epidemic is not supported by the present find-
ings as PCE users showed a highly specific personality profile that shares a number of fea-
tures with illegal stimulant users. Lastly, regular MPH use for PCE is not necessarily
associated with cognitive deficits.
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Introduction
Prescription stimulants such as methylphenidate (MPH) are controversially discussed as
potential drugs for pharmacological cognitive enhancement (PCE) in healthy individuals [1–
5]. The increase of MPH prescriptions in the past two decades was supposed to coincide with
an increased nonmedical use of MPH for PCE and relatively high prevalence rates of PCE
among college students seemed to confirm the prediction [6,7]. However, many studies failed
to clearly define “nonmedical use” and considered different substances for PCE impeding the
interpretation of the results [8]. Nevertheless, PCE is much more prevalent in the United States
compared to Europe [8], but in both regions, MPH is the most frequently misused prescription
drug for PCE [1,9].
MPH elevates the neurotransmission of dopamine and noradrenalin by reuptake inhibition
at the respective monoamine transporters, and was proposed to influence executive functions
and working memory in healthy individuals [10,11]. However, potential benefits and risks of
PCE are both modulated by individual differences in response to drugs further depending on
drug dose and task requirements. Consequently, procognitive effects of MPH are baseline-
dependent (e.g., amelioration at low and impairment at high baseline performance) and
afflicted with several trade-offs (e.g., improvement in one cognitive domain with the cost of
impairments in other cognitive domains) as well as psychiatric side-effects [10–14].
The use of MPH for the treatment of ADHD is well-established and the potential side-
effects are justified by the proven effectiveness [15]. However, this does not reclaim the use by
healthy individuals without cognitive deficits. So far, it is unclear whether regular MPH use for
PCE in healthy individuals is related to negative long-term cognitive, psychopathological, and
neurobiological consequences [10,14]. Nonetheless, previous studies found a higher prevalence
of PCE among students with lower grades [1,16,17]. In general, the misuse of prescription stim-
ulants might be associated with neuropsychological deficits prior to or as a consequence of
PCE. Reske and colleagues found that occasional prescription stimulant users showed
enhanced verbal fluency but, at the same time, more deficits in verbal learning, memory, and
cognitive flexibility compared to stimulant-naïve controls. Therefore, they suggested that pre-
existing cognitive deficits and subtle executive dysfunctions might be predictors for stimulant
use [18,19]. On the other hand, PCE itself might cause drug induced cognitive impairments as
shown in a recent longitudinal study with recreational cocaine users [20]. Accordingly, the use
of MPH might affect neuroplasticity and may, therefore, alter cognitive function, behavior, and
personality of users [21].
Like amphetamine, MPH is a phenylethylamine derivate but shares the mechanism of cate-
cholamine reuptake inhibition with cocaine [10]. The Zurich Cocaine Cognition Study
(ZuCo2St) revealed that not only dependent but also recreational cocaine users showed signifi-
cant deficits in the cognitive domains of attention, working and long-term memory, and execu-
tive functions [22]. Cocaine users also revealed higher levels of self-reported impulsivity and
novelty seeking and more ADHD symptoms compared to stimulant-naïve controls [22,23].
Moreover, cocaine use was associated with reduced neural sensitivity to social reward poten-
tially explaining the users’ deficits in social interactions such as less emotional empathy and a
smaller social network [24,25]. Studies considering the nonmedical use of MPH in healthy
individuals have only addressed acute MPH effects on social cognition and behavior [26,27],
while the effects of chronic MPH use on social behavior are unknown so far.
The bioethical debate on neuroenhancement is based on the assumption that the use of
putatively neuroenhancing stimulants already appears to be highly popular and that PCE use
will further spread in the near future. However, these assumptions have been recently disputed
[14,28]. One argument against a future epidemic of PCE is that not everyone is equally
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interested in cognitive enhancement [29] assuming that personality has an essential impact on
the willingness to use PCE [14]. Surprisingly, the influence of personality on the preference of
PCE has scarcely been investigated yet, but Quednow proposed that in particular narcissistic
and ambitious people might be more interested in PCE [14]. Preliminary data recently sug-
gested that PCE is positively associated with ADHD symptoms, sensation seeking, and impul-
sivity [17,30]. As the research on the so-called “dark triad” of personality traits revealed that
subclinical narcissism is closely related to Machiavellianism and subclinical psychopathy [31],
manipulative, opportunistic, and antisocial behaviors might be potential personality features of
PCE users as well.
The primary goal of the present study was, therefore, a broad characterization of recently
abstinent PCE users regarding their cognitive, behavioral, and personality profile. Based on
previous studies showing a higher prevalence of PCE in students with lower grades [1,16,17]
and demonstrating cognitive impairment in cocaine and other stimulant drug users [18–
20,22], we hypothesized that MPH misuse for PCE is associated with lower cognitive perfor-
mance. Moreover, in PCE users we expected an increase in psychopathological loads and a spe-
cific personality structure similar to recreational stimulant users [23,25,32]. Specifically, we
expected that PCE users show more pronounced narcissistic, opportunistic, Machiavellian, and
impulsive facets, and less prominent sociable and prosocial behaviors.
Methods
Participants
Participants were recruited through flyer advertisements at the University of Zurich and the
Swiss Federal Institute of Technology in Zurich, internet advertisement, and via e-mail as
study participants from an earlier study on PCE had consented to be contacted again [9]. All
participants had to pass an initial telephone screening to assess basic eligibility before they
were invited for the assessment at the Psychiatric Hospital of the University of Zurich. Recently
abstinent PCE users had to meet the following inclusion criteria: regular MPH use explicitly for
PCE during the past 6 months and lifetime use of MPH for PCE on at least 25 occasions. Fur-
ther inclusion criteria for all participants were 20 to 50 years of age and sufficient knowledge of
German language. Exclusion criteria for all participants implied the following conditions: 1)
severe medical diseases such as cardiovascular diseases, cancer, HIV, hepatitis, and diabetes; 2)
present or prior axis-I psychiatric disorder according to DSM-IV; 3) no family history of a
severe DSM-IV psychiatric disorder such as schizophrenia, bipolar disorder, or obsessive-com-
pulsive disorder; 4) lifetime history of a neurological disorder such as meningitis, epilepsy,
Tourette syndrome, Parkinson’s disease, dementia, and head injury including loss of con-
sciousness for more than 30 sec; 5) lifetime history of heroin use; 6) daily use of cannabis; 7)
regular use of prescription drugs with effects on the central nervous system; and 8) use of other
illegal drugs not mentioned before on more than 50 occasions. Prior to the testing session, par-
ticipants had to abstain fromMPH and illegal drugs for at least 72 hours and from alcohol for
24 hours. Adherence with these instructions was assessed by urine testing as described before
[22]. The study was approved by the Cantonal Ethics Committee of Zurich. All study partici-
pants provided informed consent after being fully informed about the study details.
Drug use
Current and past use of illegal substances and prescription drugs was assessed by a standard-
ized Interview for Psychotropic Drug Consumption considering the date of last use, average
quantity (mg, g, tablets, etc.) used weekly, and total lifetime duration of use [33]. Moreover,
urine and hair testing revealed objective quantitative results about recent and past drug use.
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Urine samples were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/
MS) regarding MPH and ritalinic acid (S1 Method) and by a semi-quantitative enzyme multi-
plied immunoassay method using a Dimension RXL Max (Siemens, Erlangen, Germany) for
all other drugs [22]. MPH and illegal drug use during the past 6 months was assessed by 6-cm
hair samples analyzed by LC-MS/MS as described in detail in S2 Method [22].
Cognitive functions
For matching reasons, premorbid verbal intelligence was assessed by the Multiple-Choice
Vocabulary Test (MWT-B). The following classical neuropsychological tests were used to
assess cognition of PCE users and stimulant-naïve controls: four tests of the Cambridge Neuro-
psychological Test Automated Battery (CANTAB) were used to test sustained attention (Rapid
Visual Processing, RVP), visuo-spatial memory (Paired Associates Learning, PAL), Spatial
Working Memory (SWM), and Intra-Extra-Dimensional Set-Shifting (IED); the Letter-Num-
ber-Sequencing Task (LNST) was used to test verbal working memory; and the Rey Auditory
Verbal Learning Test (RAVLT) was applied to test declarative verbal memory functions. Simi-
lar to our previous studies with cocaine users, four main z-scored cognitive domains (attention,
working memory, declarative memory, executive functions) were defined and equally inte-
grated in a global cognitive index (GCI, for details regarding the construction of the cognitive
domains see S3 Method) [20,22]. Furthermore, the Iowa Gambling Task (IGT) was used to
measure decision-making. Points gained in the IGT were converted into Swiss Francs and dis-
bursed to the participants.
Social cognition, interaction, and function
Social cognitive functions such as cognitive and emotional empathy as well as theory-of-mind
(ToM) were assessed with the Multifaceted Empathy Test (MET) and with the Movie for the
Assessment of Social Cognition (MASC), respectively. Moreover, the Distribution Game and
the Dictator Game tested social decision-making in an interaction paradigm, while the Social
Network Questionnaire (SNQ) provided the number of currently available social contacts.
Points gained in both interactive games were converted into Swiss Francs and disbursed to the
participants. All tests have been described in detail before [24,25].
Personality and psychiatric symptoms
Psychiatric symptoms and personality disorders were assessed using the ADHD Self-Rating
scale (ADHS-SR), the Structured Clinical Interview for DSM-IV Axis I (SCID-I Interview) and
Axis II (SCID-II Questionnaire), and the Beck Depression Inventory (BDI). The Barratt Impul-
siveness Scale (BIS-11), the Temperament Character Inventory (TCI), and the Machiavellian-
ism questionnaire (MACH-IV) were included to assess personality. Additionally, the Delay
Discounting task (DD) was used to assess delay of gratification/reward impulsivity (references
to the neuropsychological tasks and all questionnaires are provided in Table A in S1 File).
Statistical analysis
PCE users were matched with stimulant-naïve controls on the following variables: age, sex,
years of education, proportion of students, verbal intelligence, and proportion of smokers.
Quantitative data were analyzed by independent t-tests in order to compare PCE users with
controls. For qualitative data, Chi2-tests were applied. Person’s product moment correlations
were used to evaluate the association between MPH use, cognitive performance, and personal-
ity scores and to explore inter-correlations between variables with significant group differences.
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All statistical analyses were conducted using SPSS Statistics 22 (Dynelytics, Zurich, Switzer-
land). For group comparisons, p< 0.050 was set as the significance level, while for correlation
analyses the significance threshold was set at p< 0.010 in order to avoid an accumulation of
alpha-error.
Results
Ninety-four PCE users contacted us and showed interest in study participation. After a careful
telephone screening, we were able to test 32 regular PCE users but only 25 of them met all
inclusion criteria and were included in the final analyses (the trial profile is shown in Fig 1).
Fig 1. Trial profile. ADHD: Attention Deficit Hyperactivity Disorder, ADHD-SR: Attention Deficit Hyperactivity Disorder Self-Rating scale, BIS-11: Barratt
Impulsiveness Scale-11, CANTAB: Cambridge Neuropsychological Test Automated Battery, DD: Delay Discounting task, IDPC: Standardized Interview for
Psychotropic Drug Consumption (self-report), IED: Intra-Extra Dimensional Set-Shifting, IGT: Iowa Gambling Task, LNST: Letter Number Sequencing Task,
MASC: Movie for the Assessment of Social Cognition, MET: Multifaceted Empathy Test, MDMA: 3,4-Methylendioxy-N-methylamphetamin, MPH:
methylphenidate, PAL: Paired Associates Learning, PCE: pharmacological cognitive enhancement, RAVLT: Rey Auditory Verbal Learning Test, RVP: Rapid
Visual Information Processing, SCID I/II: Structural Clinical Interview for DSM-IV Axis I/II Disorders, SWM: Spatial Working Memory, TCI: Temperament and
Character Inventory.
doi:10.1371/journal.pone.0129805.g001
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PCE users were matched with 39 stimulant-naïve controls that were tested in the same way. As
intended by the matching procedure both groups did not differ regarding age, sex, student sta-
tus, years of education, verbal IQ, and smoking status, but PCE users reported significantly
more ADHD symptoms than controls (Table 1). According to the cut-off of the ADHS-SR
questionnaire, five PCE users potentially met the DSM-IV criteria for ADHD but have not
been diagnosed with this disorder before and were thus included in the study.
On average, PCE users reported the intake of MPH for PCE since 2.8 years, used 2.5 tablets
with 10mg MPH per week, have taken 486 MPH tablets in their lifetime, and were abstinent
fromMPH since 41 days (Table 1). Six PCE users featured positive urine testing for ritalinic
acid (mean 248ng/ml, range 3–1312 ng/ml), while only one PCE user revealed small traces of
MPH (14 ng/ml). Self-reported weekly MPH use was significantly correlated with hair concen-
trations of MPH over the past 6 months (r = 0.640, p< 0.001, n = 25).
PCE users showed no significant differences in the four cognitive domains and the GCI
compared to controls (Fig 2). However, the executive functions showed a moderate effect size
(d = 0.44) with regard to a superior performance of the PCE users, which was mainly explained
by a significantly better performance in the strategy subscore of the SWM (S1 Table). In the
IGT, PCE users gained more points in a shorter time (Fig 3), showing better performance in
the second and in the fourth quartile (S1 Fig).
PCE users displayed higher levels of novelty seeking (mainly explained by significantly
higher disorderliness) and revealed lower scores in social reward dependence (primarily due to
significantly lower sentimentality) compared to controls. No group differences were found for
delay discounting, but PCE users showed elevated self-reported impulsivity in the BIS-11 (spe-
cifically in the attention subscores), higher negativistic and antisocial personality traits in the
SCID-II questionnaire, as well as higher Machiavellianism in the MACH-IV (Table 2). Com-
pared to controls, PCE users reported significantly fewer social contacts and their decisions in
the social interaction tasks were more self-serving as they gave less money to the opposite
player B while preferring higher payoffs for themselves (Table 2).
When assessing mental perspective-taking (ToM), PCE users made somewhat fewer errors
in the MASC but the difference was not significant. Although PCE users revealed a slightly
enhanced mental perspective-taking in the MASC, they showed, however, significantly lower
cognitive empathy in the MET, indicating worse emotion recognition from complex picture
material (Table 2).
Neither cognitive performance nor personality scales were correlated with any MPH con-
sumption parameters, indicating that the shown abnormalities of PCE users are likely not
drug-induced. Machiavellianism was positively correlated with the TCI novelty seeking sub-
score disorderliness and the SCID-II negativistic score but negatively correlated with TCI social
reward dependence and its subscore sentimentality. Not surprisingly, the ADHS-SR score was
highly correlated with several BIS-11 scores but also with the SCID-II negativistic score. TCI
disorderliness and the SCID-II antisocial score were positively correlated as well (S2 Table).
These correlations reflect overlapping concepts of impulsivity and sociability as measured by
the different questionnaires.
Discussion
The aim of the study was to investigate whether regular PCE users show impaired cognitive
functions and a specific pattern of personality traits. The study revealed two main findings: 1)
recently abstinent PCE users and stimulant-naïve controls performed equally in most of the
cognitive tasks but PCE users performed better in strategic thinking and decision-making, and
2) PCE users showed higher impulsivity, higher novelty seeking, higher Machiavellianism, and
Pharmacological Cognitive Enhancement Is a Question of Personality
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Table 1. Demographic characteristics and drug use of stimulant-naïve healthy controls and individuals usingmethylphenidate for the purpose of
pharmacological cognitive enhancement (PCE).
Controls (n = 39) PCE users (n = 25) X2 / t-test df p value
Demographics
Age 26.2 (5.4) 24.0 (3.0) 1.185 62 0.072
Women 18 (46%) 11 (44%) 0.029 1 0.866
Smoking status (yes) 24 (46%) 15 (44%) 0.029 1 0.866
Student status (yes) 26 (67%) 20 (80%) 1.340 1 0.247
Years of education 11.6 (1.5) 12.0 (1.0) -1.161 62 0.250
Verbal IQ (MWT-B) 106.0 (8.6) 104.8 (10.5) 0.507 62 0.614
ADHD-SR (range 0–54) 7.3 (5.1) 12.9 (8.5) -3.303 62 0.002
BDI sum score 3.5 (4.2) 4.8 (5.2) -1.029 62 0.308
Drug use
Methylphenidate
Tablets per week (10mg) 0 2.5 (3.2)
Years of use 0 2.8 (1.5)
Cumulative dose (tablets) 0 485.6 (1044.4)
Last consumption (days) NA 40.5 (52.2), n = 24
Hair analysis (pq/mg) 0 84.2 (199.1)
Alcohol
Grams per week 90.6 (77.0) 92.8 (76.0) -0.114 62 0.910
Years of use 8.6 (5) 7.2 (3.5) 1.309 62 0.195
Tobacco
Cigarettes per day 5.6 (8.0) 4.8 (6.4) 0.456 62 0.650
Years of use 5.9 (6.3) 3.7 (3.6) 1.557 62 0.125
Cannabis
Grams per week 0.2 (0.7) 0.2 (0.4) 0.570 62 0.571
Years of use 3.7 (4.4) 3.3 (3.5) 0.385 62 0.702
Cumulative dose (grams) 965.4 (4423.9) 101.3 (164.0) 0.973 62 0.334
Last consumptions (days) 740.6 (1735.0), n = 24 23.5 (24.3), n = 13 1.480 35 0.148
Positive urine testinga 4 (10%) 2 (8%) a 0.064 1 0.801
Cocaine
Grams per week 0 0.1 (0.2) -1.566 62 0.122
Years of use 0 (0) 1.1 (2.8) -2.499 62 0.015
Cumulative dose (grams) 0.2 (0.9) 15.8 (60.4) -1.620 62 0.110
Last consumptions (days) 1104.8 (947.9), n = 3 319.2 (326.4), n = 9 2.290 10 0.045
Positive urine testinga 0 0
Positive hair testinga 0 1 (4%) 1.585 1 0.280
Amphetamine
Grams per week 0 0.01 (0.02) -1.718 62 0.091
Years of use 0 (0) 0.4 (1.3) -2.064 62 0.043
Cumulative dose (grams) 0.003 (0.02) 0.6 (2.4) -1.441 62 0.155
Last consumptions (days) 547.2 (258.0), n = 2 346.4 (724.9), n = 6 0.367 6 0.726
Positive urine testinga 0 1 (4%) 1.651 1 0.199
Positive hair testinga 0 1 (4%) 1.585 1 0.280
MDMA
Tablets per week 0 0.04 (0.2) -1.399 62 0.167
Years of use 0 (0) 0.4 (1.0) -2.342 62 0.022
Cumulative dose (tablets) 0.13 (0.4) 3.4 (9.0) -2.256 62 0.028
(Continued)
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more pronounced antisocial and negativistic personality traits, in combination with lower
social reward dependence compared to controls. In line with this personality pattern, they
behaved more opportunistically in social interaction tasks, showed less cognitive empathy, and
reported having a smaller social network. Importantly, these results cannot be explained by
withdrawal effects as the mean abstinence duration fromMPH was 41 days and only one sub-
ject has shown very small traces of MPH in the urine testing.
The finding that regular PCE users showed elevated attentional impulsivity but no cognitive
impairment might indicate their motivation to use MPH for PCE. As it was shown that only
individuals with low baseline performance show cognitive improvements using stimulant
drugs [34], it is unlikely that MPH actually improved general cognitive functioning of the pres-
ent PCE users because they already performed very well and sometimes better than controls.
However, MPH is effective to treat symptoms of ADHD such as attentional impulsivity [10].
In fact, PCE users in the present study showed more ADHD symptoms and a previous study
found procognitive effects of MPH specifically in healthy individuals with high impulsivity
Table 1. (Continued)
Controls (n = 39) PCE users (n = 25) X2 / t-test df p value
Last consumption (days) 3100.8 (1289.8), n = 2 31.3 (26.0), n = 3 3.976 6 0.007
Positive hair testinga 0 2 (8%) 3.221 1 0.073
Data are means and standard deviations, or number and percent. Signiﬁcant p-values are shown in bold.
aFor cut-offs see S1 and S2 Methods.
ADHD-SR: Attention Deﬁcit Hyperactivity Disorder Self-Rating scale, BDI: Beck Depression Inventory, IQ: intelligence quotient, MWT-B: Mehrfachwahl-
Wortschatz-Test (vocabulary test), PCE: pharmacological cognitive enhancement.
doi:10.1371/journal.pone.0129805.t001
Fig 2. Mean z-scores and standard errors of means for the global cognitive index (GCI) and four cognitive domains.
doi:10.1371/journal.pone.0129805.g002
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[35]. Thus, MPH might improve impulse control of PCE users, helping them to begin and sus-
tain studying, rather than enhancing cognition directly. Consequently, not everyone benefits
fromMPH use and opposite cognitive effects (improvement and impairment) of the same
MPH dose might even occur in the same individual depending on task requirements [10,13].
As a specific predisposition such as high impulsivity is needed to benefit fromMPH use and
not everyone is willing to use PCE anyway [29], a forthcoming epidemic of MPH use for PCE
is considered unlikely.
Although the groups did not significantly differ on the SCID-II narcissistic scale as initially
hypothesized, PCE users showed more negativistic and antisocial personality traits, and higher
Machiavellianism compared to controls. Interestingly, the SCID-II narcissistic subscale was
significantly correlated with Machiavellianism (r = 0.38, p<0.010) and the SCID-II negativ-
istic subscale (r = 0.51, p<0.001), confirming that narcissism, negativism, and Machiavel-
lianism show a considerable phenomenological overlap. Thus, PCE users showed a specific
pattern of personality traits that has been conceptualized as the “dark triad” [31]. Moreover,
with their increased novelty seeking, higher impulsivity, and antisocial tendencies, PCE users
share a number of personality features with recreational stimulant users [23,36]. Additionally,
PCE users behaved less prosocial in a money distribution game similar to recreational and
dependent cocaine users as shown recently [25]. As intensity of cocaine use was not correlated
with social decision-making, Hulka et al. suggested that the opportunistic behavior of stimulant
users might be a stable trait and possibly a predisposition for the initiation of stimulant use
[25]. Furthermore, similar to cocaine users, PCE users also displayed a smaller social network
than controls [24]. This might be explained by the fact that PCE users are less sociable (as their
personality profile suggests) and, thus, less integrated in social networks. Additionally, the
smaller social network might mirror an intensified cost-benefit thinking of PCE users, and a
more strategic selection of friends as supported by the present findings in IGT decision-making
and strategic thinking.
Fig 3. Means and standard error of means of points gained and of processing time (sec) in the Iowa Gambling Task (IGT). ** p< 0.010, and
***p < 0.001.
doi:10.1371/journal.pone.0129805.g003
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Table 2. Personality traits and social cognition and interaction of stimulant-naïve healthy controls and individuals usingmethylphenidate for the
purpose of pharmacological cognitive enhancement (PCE).
Controls (n = 39) PCE users (n = 25) t-test df p value Cohen's d
Personality
BIS-11 sum score 61.6 (8.4) 66.8 (11.0) -2.145 62 0.036 0.53
BIS-11 Motor impulsiveness 21.7 (3.1) 23.9 (6.0) -1.941 62 0.057 0.49
BIS-11 Nonplanning impulsiveness 25.4 (4.2) 26.2 (5.1) -0.690 62 0.493 0.18
BIS-11 Attentional impulsiveness 14.6 (3.2) 16.8 (4.4) -2.293 62 0.025 0.57
BIS-11 Attention 9.5 (2.3) 11.1 (2.8) -2.428 62 0.018 0.60
BIS-11 Cognitive Inﬂexibility 5.1 (1.7) 14.2 (3.3) -1.284 62 0.204 0.33
TCI Novelty Seeking 21.8 (5.2) 24.6 (5.9) -2.003 62 0.050 0.50
TCI Exploratory excitability 7.9 (2.0) 8.3 (2.5) -0.804 62 0.425 0.21
TCI Impulsiveness 4.3 (2.1) 4.6 (2.2) -0.563 62 0.576 0.14
TCI Extravagance 5.4 (1.8) 5.9 (1.9) -0.946 62 0.348 0.24
TCI Disorderliness 4.2 (1.8) 5.8 (1.7) -3.566 62 0.001 0.84
TCI Harm avoidance 14.3 (5.6) 13.2 (6.9) 0.747 62 0.458 0.19
TCI Reward Dependence 16.9 (4.0) 14.6 (4.2) 2.182 62 0.033 0.54
TCI Sentimentality 6.5 (1.8) 5.4 (1.8) 2.299 62 0.025 0.57
TCI Attachment 6.5 (1.9) 5.5 (2.4) 1.850 62 0.069 0.47
TCI Dependence 4.0 (1.6) 3.7 (1.6) 0.565 62 0.574 0.15
TCI Persistence 4.3 (2.1) 3.4 (2.1) 1.681 62 0.098 0.42
TCI Self-Directedness 33.9 (6.0) 31.2 (6.4) 1.704 62 0.093 0.43
TCI Cooperativeness 33.5 (5.7) 31.5 (5.0) 1.375 62 0.174 0.35
TCI Self-Transcendence 10.2 (5.2) 9.2 (6.6) 0.695 62 0.490 0.18
SCID-II Avoidant 1.2 (1.4) 0.7 (1.1) 1.526 62 0.132 0.39
SCID-II Dependent 1.2 (1.1) 1.2 (1.0) -0.035 62 0.973 0.01
SCID-II Obsessive-compulsive 3.5 (1.8) 3.6 (1.6) -0.256 62 0.799 0.07
SCID-II Negativistic 1.2 (1.4) 2.0 (1.4) -2.486 62 0.016 0.61
SCID-II Depressive 1.1 (1.6) 1.4 (1.7) -0.559 62 0.578 0.14
SCID-II Paranoid 1.6 (1.8) 1.8 (1.9) -0.359 62 0.721 0.09
SCID-II Schizotypal 1.3 (1.6) 1.1 (1.0) 0.628 62 0.532 0.16
SCID-II Schizoid 0.7 (1.1) 1.2 (1.3) -1.699 62 0.094 0.43
SCID-II Histrionic 1.9 (1.5) 2.5 (1.9) -1.343 62 0.184 0.34
SCID-II Narcissistic 2.4 (2.5) 3.2 (2.3) -1.241 62 0.219 0.32
SCID-II Borderline 2.4 (2.1) 2.3 (2.0) 0.303 62 0.763 0.08
SCID-II Antisocial 1.9 (1.6) 3.0 (2.7) -2.011 62 0.049 0.50
Social cognition and interaction
MACH-IV sum score 89.7 (12.3) 97.0 (10.5) -2.561 61 0.013 0.64
DD k parameter all 0.012 (0.018) 0.022 (0.032) -1.615 62 0.111 0.41
MET Direct Empathy 5.1 (1.2) 4.7 (1.2) 1.426 62 0.159 0.36
MET Indirect Empathy 4.8 (1.2) 4.6 (1.3) 0.420 62 0.676 0.11
MET Cognitive Empathy 25.4 (3.8) 23.0 (4.9) 2.273 62 0.026 0.56
MASC Total ToM errors 10.2 (4.6) 8.2 (3.2) 1.905 62 0.061 0.48
Social network size (SNQ) 21.5 (7.3) 17.8 (5.3) 2.213 62 0.031 0.55
Distribution game, payoff player B 19.0 (8.0) 17.0 (9.6) 0.882 62 0.381 0.23
Dictator game, payoff player B 16.6 (12.2) 10.3 (9.4) 2.196 62 0.032 0.55
Data are means and standard deviations. Signiﬁcant p-values are shown in bold. BIS: Barratt Impulsiveness Scale, DD: Delay Discounting task,
MACH-IV: Machiavellianism Scale, MASC: Movie for the Assessment of Social Cognition, MET: Multifaceted Empathy Test, PCE: pharmacological
cognitive enhancement, SCID-II: Structural Clinical Interview for DSM-IV Axis-II Disorders, SNQ: Social network questionnaire, TCI: Temperament and
Character Inventory, ToM: Theory-of-Mind.
doi:10.1371/journal.pone.0129805.t002
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Our findings are subject to some limitations. First, the number of PCE users was relatively
small. This is obviously a threat to the statistical power of the reported analysis but, at the same
time, a further implicit result of the study. In fact, it was hard to find individuals with regular
MPH use for PCE who reported no concurrent regular use of other illegal drugs and no ADHD
diagnosis. Second, the fact that the data were restricted to PCE users, who used MPH without
regular co-use of illegal drugs of abuse, is a further limitation as it was shown previously that
PCE users show a higher prevalence of illegal drug use compared to non-users [9,17]. There-
fore, the question arises, whether we tested only a very unique group within the already very
specific group of PCE users. Nevertheless, the exclusion of PCE users with regular illegal drug
use was inevitable in order to explain differences between PCE users and controls exclusively
by the MPH use. Moreover, previous research revealed that PCE occurs most likely during
short periods of exam preparation and daily or high dose use of PCE is rare [9]. Thus, through
our inclusion criteria, we likely skimmed only the most intense PCE users. Third, we used a
cross-sectional design but a longitudinal design would have been most appropriate to investi-
gate cause-effect relationships between PCE drug use and changes in cognition and
personality.
Conclusion
This is the first study that broadly characterized individuals regularly using MPH for PCE by
applying a comprehensive neuropsychological test battery in combination with a thorough per-
sonality assessment and urine and hair testing. Our findings indicate that the regular nonmedi-
cal MPH use for PCE over more than two years was not associated with cognitive deficits. PCE
users performed equally to controls, or even better in tasks requiring strategic thinking, which
disproves the assumption that PCE is a compensation for cognitive deficits [1,16,17]. As the
personality profile of PCE users shared some features with recreational illegal stimulant users,
such as higher novelty seeking and impulsivity, we propose instead that PCE users may aim to
improve their impulse control in order to optimize their own learning compliance. PCE users
were also found to be less prosocial, less emphatic, and more Machiavellianism, which is in line
with their enhanced strategic thinking and planning behavior. Thus, PCE users may instru-
mentalize MPH as little helper [37] in order to maximize their own benefits. Finally, the overall
personality profile of PCE users is highly specific disproving the often made assumption that
PCE will widely spread in society.
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